{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:07:58Z","timestamp":1774080478308,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100022600","name":"Wan Fang Hospital","doi-asserted-by":"publisher","award":["110wf-phd-01"],"award-info":[{"award-number":["110wf-phd-01"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["112TMUH-NE-06"],"award-info":[{"award-number":["112TMUH-NE-06"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12012-026-10102-1","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:44:27Z","timestamp":1771303467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Risk and Prediction Model of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors in Patients with Liver Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Yen-Chou","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ming","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bagas Suryo","family":"Bintoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-I","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"10102_CR1","unstructured":"National Cancer Institute (2013). Cancer stat facts: liver and intrahepatic bile duct cancer. Retrieved January 8, 2024, from: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html"},{"key":"10102_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi, A., & Mannucci, P. M. (2011). The coagulopathy of chronic liver disease. New England Journal of Medicine, 365, 147\u2013156. https:\/\/doi.org\/10.1056\/NEJMra1011170","journal-title":"New England Journal of Medicine"},{"key":"10102_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110450","author":"A Zanetto","year":"2018","unstructured":"Zanetto, A., Campello, E., Spiezia, L., Burra, P., Simioni, P., & Russo, F. P. (2018). Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10110450","journal-title":"Cancers (Basel)"},{"key":"10102_CR4","unstructured":"National Comprehensive Cancer Network (2023). Hepatocellular Carcinoma (Version 2.2023). Retrieved September 14, 2023, from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf"},{"key":"10102_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","volume":"25","author":"M Totzeck","year":"2018","unstructured":"Totzeck, M., Mincu, R. I., Mrotzek, S., Schadendorf, D., & Rassaf, T. (2018). Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. European Journal of Preventive Cardiology, 25, 482\u2013494. https:\/\/doi.org\/10.1177\/2047487318755193","journal-title":"European Journal of Preventive Cardiology"},{"key":"10102_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir, H., Ethier, J. L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2017). Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treatment Reviews, 53, 120\u2013127. https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.002","journal-title":"Cancer Treatment Reviews"},{"key":"10102_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.critrevonc.2012.12.006","volume":"87","author":"G Sonpavde","year":"2013","unstructured":"Sonpavde, G., Je, Y., Schutz, F., Galsky, M. D., Paluri, R., Rosenberg, J. E., Bellmunt, J., & Choueiri, T. K. (2013). Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology\/Hematology, 87, 80\u201389. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.006","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10102_CR8","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/s0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., & George, S. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor Sunitinib. Lancet, 370, 2011\u20132019. https:\/\/doi.org\/10.1016\/s0140-6736(07)61865-0","journal-title":"Lancet"},{"key":"10102_CR9","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1158\/1078-0432.Ccr-16-2869","volume":"23","author":"V Narayan","year":"2017","unstructured":"Narayan, V., Keefe, S., Haas, N., Wang, L., Puzanov, I., Putt, M., Catino, A., Fang, J., Agarwal, N., Hyman, D., & Smith, A. M. (2017). Prospective evaluation of Sunitinib-Induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 23, 3601\u20133609. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2869","journal-title":"Clinical Cancer Research"},{"key":"10102_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMc1108849","volume":"365","author":"I Uraizee","year":"2011","unstructured":"Uraizee, I., Cheng, S., & Moslehi, J. (2011). Reversible cardiomyopathy associated with Sunitinib and Sorafenib. New England Journal of Medicine, 365, 1649\u20131650. https:\/\/doi.org\/10.1056\/NEJMc1108849","journal-title":"New England Journal of Medicine"},{"key":"10102_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo, G., Autorino, R., Bruni, G., Carteni, G., Ricevuto, E., Tudini, M., Ficorella, C., Romano, C., Aieta, M., Giordano, A., & Giuliano, M. (2009). Cardiovascular toxicity following Sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Annals of Oncology, 20, 1535\u20131542. https:\/\/doi.org\/10.1093\/annonc\/mdp025","journal-title":"Annals of Oncology"},{"key":"10102_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100338","volume":"7","author":"P Vallerio","year":"2022","unstructured":"Vallerio, P., Orenti, A., Tosi, F., Maistrello, M., Palazzini, M., Cingarlini, S., Colombo, P., Bertuzzi, M., Spina, F., Amatu, A., & Lombardo, R. (2022). Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: A real-life study and proposed algorithm for proactive management. ESMO Open, 7, Article 100338. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100338","journal-title":"ESMO Open"},{"key":"10102_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaccao.2022.05.002","volume":"4","author":"DY Chen","year":"2022","unstructured":"Chen, D. Y., Liu, J. R., Tseng, C. N., Hsieh, M. J., Chuang, C. K., Pang, S. T., Chen, S. W., Hsieh, I. C., Chu, P. H., Chen, J. S., & Wen-Cheng, Chang J. (2022). Major adverse cardiovascular events in patients with renal cell carcinoma treated with targeted therapies. JACC: CardioOncology, 4, 223\u2013234. https:\/\/doi.org\/10.1016\/j.jaccao.2022.05.002","journal-title":"JACC: CardioOncology"},{"key":"10102_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.030263","volume":"13","author":"YC Chen","year":"2024","unstructured":"Chen, Y. C., Huang, C. Y., Lien, L. M., Chen, J. H., & Hsieh, F. I. (2024). Cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in taiwan: A nested Case-Control study. Journal of the American Heart Association, 13, Article e030263. https:\/\/doi.org\/10.1161\/jaha.123.030263","journal-title":"Journal of the American Heart Association"},{"key":"10102_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/JCMA.0000000000001026","volume":"87","author":"YC Chen","year":"2024","unstructured":"Chen, Y. C., Chen, J. H., & Hsieh, F. I. (2024). Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis. Journal of the Chinese Medical Association, 87, 48\u201357.","journal-title":"Journal of the Chinese Medical Association"},{"key":"10102_CR16","doi-asserted-by":"publisher","unstructured":"Lyon, A. R., L\u00f3pez-Fern\u00e1ndez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Jutta Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., Azambuja, E., Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., Meer, P., Pal, H. J. H., & ESC Scientific Document Group. . (2022). 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). European Heart Journal, 43, 4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"10102_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/phar.2896","volume":"44","author":"F Yuan","year":"2024","unstructured":"Yuan, F., Lenneman, C., Krone, R., Williams, G. R., Outlaw, D., Jr., Katsnelson, M., & Lirette, S. (2024). Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy, 44, 214\u2013223. https:\/\/doi.org\/10.1002\/phar.2896","journal-title":"Pharmacotherapy"},{"key":"10102_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis, 5, 632\u2013634. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10102_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/ceor.S39964","volume":"5","author":"AA Khorana","year":"2013","unstructured":"Khorana, A. A., Dalal, M. R., Lin, J., & Connolly, G. C. (2013). Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. ClinicoEconomics and Outcomes Research, 5, 101\u2013108. https:\/\/doi.org\/10.2147\/ceor.S39964","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"10102_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","volume":"118","author":"CJ Chiang","year":"2019","unstructured":"Chiang, C. J., Wang, Y. W., & Lee, W. C. (2019). Taiwan\u2019s nationwide cancer registry system of 40 years: Past, present, and future. Journal of the Formosan Medical Association, 118, 856\u2013858. https:\/\/doi.org\/10.1016\/j.jfma.2019.01.012","journal-title":"Journal of the Formosan Medical Association"},{"key":"10102_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/clep.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh, C. Y., Su, C. C., Shao, S. C., Sung, S. F., Lin, S. J., Kao Yang, Y. H., & Lai, E. C. (2019). Taiwan\u2019s National health insurance research database: Past and future. Clinical Epidemiology, 11, 349\u2013358. https:\/\/doi.org\/10.2147\/clep.S196293","journal-title":"Clinical Epidemiology"},{"key":"10102_CR22","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/s0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000). Development of a comorbidity index using physician claims data. Journal of Clinical Epidemiology, 53, 1258\u20131267. https:\/\/doi.org\/10.1016\/s0895-4356(00)00256-0","journal-title":"Journal of Clinical Epidemiology"},{"key":"10102_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011). A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 64, 749\u2013759. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004","journal-title":"Journal of Clinical Epidemiology"},{"key":"10102_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/oxfordjournals.aje.a114001","volume":"121","author":"EL Frome","year":"1985","unstructured":"Frome, E. L., & Checkoway, H. (1985). Use of Poisson regression mmodels in estimating incidence rates and ratios. American Journal of Epidemiology, 121, 309\u2013323. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114001","journal-title":"American Journal of Epidemiology"},{"key":"10102_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/circulationaha.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin, P. C., Lee, D. S., & Fine, J. P. (2016). Introduction to the analysis of survival data in the presence of competing risks. Circulation, 133, 601\u2013609. https:\/\/doi.org\/10.1161\/circulationaha.115.017719","journal-title":"Circulation"},{"key":"10102_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch, P. M., & Therneau, T. M. (1994). Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81, 515\u2013526. https:\/\/doi.org\/10.1093\/biomet\/81.3.515","journal-title":"Biometrika"},{"key":"10102_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2307\/2337177","volume":"80","author":"DY Lin","year":"1993","unstructured":"Lin, D. Y., Wei, L. J., & Ying, Z. (1993). Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika, 80, 557\u2013572. https:\/\/doi.org\/10.2307\/2337177","journal-title":"Biometrika"},{"key":"10102_CR28","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","unstructured":"D\u2019Agostino, R. B., Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17, 2265\u20132281.","journal-title":"Statistics in Medicine"},{"key":"10102_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70, 41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41","journal-title":"Biometrika"},{"key":"10102_CR30","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/eurheartj\/ehz460","volume":"40","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir, H., Thavendiranathan, P., Austin, P. C., Lee, D. S., Amir, E., Tu, J. V., Fung, K., & Anderson, G. M. (2019). Development and validation of A multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: A population-based cohort study. European Heart Journal, 40, 3913\u20133920. https:\/\/doi.org\/10.1093\/eurheartj\/ehz460","journal-title":"European Heart Journal"},{"key":"10102_CR31","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1002\/sim.6994","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin, P. C., Lee, D. S., D\u2019Agostino, R. B., & Fine, J. P. (2016). Developing points-based risk-scoring systems in the presence of competing risks. Statistics in Medicine, 35, 4056\u20134072. https:\/\/doi.org\/10.1002\/sim.6994","journal-title":"Statistics in Medicine"},{"key":"10102_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","volume":"15","author":"M Wolbers","year":"2014","unstructured":"Wolbers, M., Blanche, P., Koller, M. T., Witteman, J. C., & Gerds, T. A. (2014). Concordance for prognostic models with competing risks. Biostatistics, 15, 526\u2013539. https:\/\/doi.org\/10.1093\/biostatistics\/kxt059","journal-title":"Biostatistics"},{"key":"10102_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/biom.12232","volume":"71","author":"P Blanche","year":"2015","unstructured":"Blanche, P., Proust-Lima, C., Loubere, L., Berr, C., Dartigues, J. F., & Jacqmin-Gadda, H. (2015). Quantifying and comparing dynamic predictive accuracy of joint models for longitudinal marker and time-to-event in presence of censoring and competing risks. Biometrics, 71, 102\u2013113. https:\/\/doi.org\/10.1111\/biom.12232","journal-title":"Biometrics"},{"key":"10102_CR34","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche, P., Dartigues, J. F., & Jacqmin-Gadda, H. (2013). Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Statistics in Medicine, 32, 5381\u20135397. https:\/\/doi.org\/10.1002\/sim.5958","journal-title":"Statistics in Medicine"},{"key":"10102_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.21037\/atm.2018.07.38","volume":"6","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Cortese, G., Combescure, C., Marshall, R., Lee, M., Lim, H. J., & Haller, B. (2018). Overview of model validation for survival regression model with competing risks using melanoma study data. Annals of Translational Medicine, 6, 325. https:\/\/doi.org\/10.21037\/atm.2018.07.38","journal-title":"Annals of Translational Medicine"},{"key":"10102_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical Prediction Models: A Practical Approach to Development, Validation and Updating","author":"EW Steyerberg","year":"2009","unstructured":"Steyerberg, E. W. (2009). Clinical Prediction Models: A Practical Approach to Development, Validation and Updating. Springer."},{"key":"10102_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-7792-1","volume-title":"Converting data into evidence: A statistics primer for the medical practitioner","author":"A DeMaris","year":"2013","unstructured":"DeMaris, A., & Selman, S. H. (2013). Converting data into evidence: A statistics primer for the medical practitioner. Springer."},{"key":"10102_CR38","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. The New England Journal of Medicine, 375, 1457\u20131467. https:\/\/doi.org\/10.1056\/NEJMra1100265","journal-title":"The New England Journal of Medicine"},{"key":"10102_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yjmcc.2021.12.013","volume":"165","author":"AH Baik","year":"2022","unstructured":"Baik, A. H. (2022). Hypoxia signaling and oxygen metabolism in cardio-oncology. Journal of Molecular and Cellular Cardiology, 165, 64\u201375. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.12.013","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10102_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103186","volume":"157","author":"A Das","year":"2021","unstructured":"Das, A., Mahapatra, S., Bandyopadhyay, D., Samanta, S., Chakraborty, S., Philpotts, L. L., Jahangir, E., & Roy, B. (2021). Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews in Oncology\/Hematology, 157, Article 103186. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103186","journal-title":"Critical Reviews in Oncology\/Hematology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10102-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:04:51Z","timestamp":1774076691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10102"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10102-1","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}